# Joy Duemke

Joy Duemke writes and speaks about blood supply resilience, partnerships between blood manufacturers and blood centers, and changes in blood product manufacturing, including platelet production and cell collection for gene therapy.

- Profile: https://b2binfluencer.marketing/creators/joy-duemke/
- LinkedIn: https://www.linkedin.com/in/joy-duemke-339a922
- LinkedIn followers: 1,866
- Based on 12 dated posts, latest 2026-09-30

## Summary

Joy Duemke is most useful for concise views on blood supply resilience and blood product manufacturing.

- Best for: A blood technology or biotech company seeking partnerships and resilience thought leadership.
- Not for: Consumer reach, quick product sales, or direct clinical outcome claims.
- Check first: Confirm audience analytics, job titles, and any sponsorship terms before contacting them.

### Takeaways

- Partnerships between manufacturers and blood centers should be built before a crisis, not during one.
- Automated whole-blood platelet processing relates to supply, efficiency, and consistency.
- Cell collection for gene therapy can be difficult for some genetic hemoglobinopathy patients.

## Main ideas

- **The blood supply's support system stays invisible until it fails, so partnerships should be built before a crisis**: Duemke's core argument is about timing. The manufacturers, logistics networks, blood centers, and advocacy frameworks that keep blood moving are largely out of sight until a crisis exposes them, so the partnerships that hold the system together have to exist in advance rather than be improvised under pressure. They name three components of that partnership — transparency, mutual investment, and a unified advocacy voice — and frame working together as both good business and what patients depend on.
- **Disruption is something to grow through, and the way forward is one voice aimed at policymakers**: Duemke treats tariff volatility, cybersecurity threats, and supply chain fragmentation as live pressures on the U.S. blood supply — and argues that the response is collective rather than individual. When manufacturers and blood centers speak as one to policymakers, to CMS, and to the public, they raise what is at stake and grow the whole ecosystem. They describe true partnership as sharing not just supply chain visibility but the message itself: blood is essential, deserves investment, and saves lives.
- **Technical bottlenecks in collection and manufacturing are addressed through professional education**: Two posts follow the same pattern: state the operational or clinical problem plainly, name the patient group or process affected, then direct readers to an accredited education program. One concerns collecting enough high-quality hematopoietic progenitor cells for gene therapy, which is difficult for patients with genetic hemoglobinopathies because the underlying disease affects mobilization. The other concerns platelet manufacturing moving from manual, apheresis-based collection toward automated whole blood processing, with supply, efficiency, and product consistency as the questions that shift raises. In both, Duemke frames the problem and points readers to training.
- **Crediting partners and faculty by name is part of the argument**: Across the posts, Duemke attributes the work to the organizations and people who do it — AABB and Dr. John Manis for the collection program, Wiley Health Learning and Terumo Blood and Cell Technologies for the platelet module — and keeps the partner's role visible rather than absorbing it into a first-person claim. The posts reflect the partnership argument: the ecosystem advances together.

## Work to read

- [Building Resilience in Uncertain Times](https://www.linkedin.com/posts/joy-duemke-339a922_when-a-crisis-hits-the-blood-supply-becomes-activity-7462505056739696641-fuYJ)
- [Global Pressures on the U.S. Blood Supply: The New Reality of Internationalized Blood Operations](https://www.linkedin.com/posts/joy-duemke-339a922_bloodbanking-supplychain-abcannualmeeting-activity-7437903866614145024-EnmW)
- [Optimizing Apheresis Starting Material Collections for Stem Cell Gene Therapy Manufacturing for Patients with Genetic Hemoglobinopathies](https://www.linkedin.com/posts/joy-duemke-339a922_gene-therapy-is-creating-new-possibilities-activity-7484976356620140544-bo4a)
- [From Manual to Automated Platelet Production](https://www.linkedin.com/posts/joy-duemke-339a922_platelet-manufacturing-is-evolving-beyond-activity-7483515438526529536-L0P_)

## Brand relationships

- **AABB** (mention)
- **America's Blood Centers** (mention)
- **Wiley Health Learning** (disclosed_partnership)
- **Terumo Blood and Cell Technologies** (disclosed_partnership)
- **Substack** (mention)

## Partnerships

The posts do not document any partnership or sponsorship format that Joy Duemke offers. They describe collaboration between blood manufacturers and blood centers and promote third-party educational programs—an AABB webinar on cell collection for gene therapy and a Wiley Health Learning CME module supported by Terumo Blood and Cell Technologies—but do not state that Duemke was paid or engaged as a sponsor. No rate, deliverable or package is listed. A brand considering sponsorship should request terms and format details directly.

## Alternatives

- Hussain Mooraj: Choose Hussain Mooraj when a campaign centers on patient access and commercial delivery for cell and gene therapies, especially in Europe. The posts describe a Rome working group where fewer than one in five eligible patients can access therapies, with panels repeatedly returning to access as the frontier. They also cover a Deloitte NextGen Therapies summit on clinical-to-commercial planning, site readiness, reimbursement, and supply-chain enablement. For a blood-technology or biotech company seeking to convene payers, providers, manufacturers, and investors around access, Mooraj offers a closer starting point than Duemke's blood-center resilience framing.
- Dan Lewis: Choose Dan Lewis when a campaign needs a broad pharma-manufacturing audience and a news or integration angle, rather than a blood-supply resilience specialist. One post is a pharma industry roundup covering licensing, FDA leadership turnover, restructuring, drug sales, and manufacturing policy. The other marks the completion of an acquisition combining automation and digital manufacturing with project delivery, CQV, quality, and operational readiness. For a partner seeking to reach pharma manufacturing and facility-lifecycle buyers with a supply-chain visibility message, Lewis offers a wider industry-news and integration platform.
- Armin Metzger: Choose Armin Metzger when a campaign focuses on senior manufacturing and supply leadership at scale, European biologics manufacturing, or biosimilar access. The posts cover a decade leading manufacturing and supply operations and R&D at Ferring, including FDA approvals for a microbiome-based therapy and an oncology gene therapy. They also cover the opening of a high-volume biosimilar manufacturing centre in Lendava, Slovenia, tied to a portfolio ambition and patient access. For a company seeking an executive voice on facility scale-up, supply reliability, and access through biosimilars, Metzger is a stronger fit than Duemke's blood-supply partnership framing.

---
AI-assisted summary of public posts. Audience demographics are not available. Engagement appears only where we checked recent posts. Method: https://b2binfluencer.marketing/methodology/